Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8565703 | 0.83 | ALDH1A1 (0.45) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL8568179 | 0.80 | ALDH1A1 (0.53) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| Ethylene SCHEMBL27749127 | 0.77 | ALDH1A1 (0.50) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL12343951 | 0.76 | ALDH1A1 (0.46) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL1085604 | 0.75 | ALDH1A1 (0.57) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL2602389 | 0.75 | ALDH1A1 (0.54) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL319309 | 0.75 | ALDH1A1 (0.49) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL227454 | 0.75 | ALDH1A1 (0.49) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL56332 | 0.75 | ALDH1A1 (0.49) | ALDH1A1HTTRAB9AMAPTMEN1 | |
| SCHEMBL10734254 | 0.75 | ALDH1A1 (0.49) | ALDH1A1HTTRAB9AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | CTXT PTY LIMITED (AU) | 2021-12-09 | — | — | US | disclosed |
| EP-3676266-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | Ctxt Pty Ltd (AU) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019043139-A1 | FUSED [1,2,4]THIADIAZINE DERIVATIVES WHICH ACT AS KAT INHIBITORS OF THE MYST FAMILY | CTXT PTY LIMITED (AU) | 2019-03-07 | — | — | WO | disclosed |
| EP-1789391-B1 | BIVALENT LINKERS AND CONJUGATES THEREOF | ENDOCYTE INC (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2129224-B1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-9156832-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9156832-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20150065492-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065492-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2015-03-05 | — | — | US | disclosed |
| US-8765741-B2 | 5,6-dihydro-1H-pyridin-2-one compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2008124450-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-0932405-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BECKMAN CORP (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6218539-B1 | PHENYL UREAS | SMITHKLINE BEECHAM CORPORATION | 2001-04-17 | — | — | US | disclosed |
| EP-0932405-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-08-04 | — | — | EP | disclosed |
| WO-1997049400-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-12-31 | — | — | WO | disclosed |
| US-4748172-A | 3-bicyclicpyridinium-methyl cephalosporins | ELI LILLY AND COMPANY (US) | 1988-05-31 | — | — | US | disclosed |
| US-4692443-A | 3-bicyclicpyridinium-methyl cephalosporins | ELI LILLY AND COMPANY (US) | 1987-09-08 | — | — | US | disclosed |
| EP-0138552-A2 | Improvements on or relating to 3-bicyclicpyridinium-methyl cephalosporins | ELI LILLY AND COMPANY (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4451650-A | ANTITUMOR AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1984-05-29 | — | — | US | disclosed |
| EP-0107130-A1 | Pyrido(4,3-b)(1,4) oxazines and pyrido(4,3-b) (1,4)thiazines | Southern Research Institute (US) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380548-A1 | Fused [1,2,4]Thiadiazine Derivatives Which Act as KAT Inhibitors of the MYST Family | KAT5, KAT6A, KAT2A | ALDH1A1 2920/4885HTT 1042/4885RAB9A 3489/4885 |
| US-20150065492-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, PYGL, HCCS | ALDH1A1 417/4885HTT 3609/4885RAB9A 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.